Cost-effectiveness of rotavirus vaccination in Mozambique

Detalhes bibliográficos
Autor(a) principal: Lourenço Guimarães, Esperança
Data de Publicação: 2022
Outros Autores: Chissaque, Assucênio, Pecenka, Clint, Clark, Andrew, Vaz, Basília, Banze, Arlindo, Canana, Neide, Romão, Clésio, do Rosário Oliveira Martins, Maria, de Deus, Nilsa, Debellut, Frédéric
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/145718
Resumo: Funding Information: The authors received funding from Bill and Melinda Gates Foundation (OPP1147721), through PATH subaward number: GAT.2111-01707508-SUB. Funding Information: We thank the EPI and the NITAG, from Mozambique for their support and commitment to the present analysis. We also thank PATH team for the technical support and Laura Kallen (from PATH) for linguistic revision of the manuscript. The authors received funding from Bill and Melinda Gates Foundation (OPP1147721), through PATH subaward number: GAT.2111-01707508-SUB. Publisher Copyright: © 2022 The Authors
id RCAP_826f4529f6f7101910a66462bafa1816
oai_identifier_str oai:run.unl.pt:10362/145718
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Cost-effectiveness of rotavirus vaccination in MozambiqueCost-effectivenessDiarrheaModellingMozambiqueRotavirusUNIVACVaccinationMolecular MedicineImmunology and Microbiology(all)veterinary(all)Public Health, Environmental and Occupational HealthInfectious DiseasesSDG 3 - Good Health and Well-beingFunding Information: The authors received funding from Bill and Melinda Gates Foundation (OPP1147721), through PATH subaward number: GAT.2111-01707508-SUB. Funding Information: We thank the EPI and the NITAG, from Mozambique for their support and commitment to the present analysis. We also thank PATH team for the technical support and Laura Kallen (from PATH) for linguistic revision of the manuscript. The authors received funding from Bill and Melinda Gates Foundation (OPP1147721), through PATH subaward number: GAT.2111-01707508-SUB. Publisher Copyright: © 2022 The AuthorsIntroduction: Rotavirus is one of the most common cause of severe gastroenteritis in children, with the largest mortality burden in low- and middle-income countries. To prevent rotavirus gastroenteritis, Mozambique introduced ROTARIX® vaccine in 2015, however, its cost-effectiveness has never been established in the country. In 2018, additional vaccines became available globally. This study estimates the cost-effectiveness of the recently introduced ROTARIX in Mozambique and compares the cost-effectiveness of ROTARIX®, ROTAVAC®, and ROTASIIL® to inform future use. Methods: We used a decision-support model to calculate the potential cost-effectiveness of vaccination with ROTARIX compared to no vaccination over a five-year period (2016–2020) and to compare the cost-effectiveness of ROTARIX, ROTAVAC, and ROTASIIL to no vaccination and to each other over a ten-year period (2021–2030). The primary outcome was the incremental cost per disability-adjusted life-year (DALY) averted from a government perspective. We assessed uncertainty through sensitivity analyses. Results: From 2016 to 2020, we estimate the vaccine program with ROTARIX cost US$12.3 million, prevented 4,628 deaths, and averted US$3.1 million in healthcare costs. The cost per DALY averted was US$70. From 2021 to 2030, we estimate all three vaccines could prevent 9,000 deaths and avert US$7.8 million in healthcare costs. With Global Alliance for Vaccines and Immunization (Gavi) support, ROTARIX would have the lowest vaccine program cost (US$31 million) and 98 % probability of being cost-effective at a willingness-to-pay threshold of 0.5x GDP per capita. Without Gavi support, ROTASIIL would have the lowest vaccine program cost (US$75.8 million) and 30 % probability of being cost-effective at the same threshold. Conclusion: ROTARIX vaccination had a substantial public health impact in Mozambique between 2016 and 2020. ROTARIX is currently estimated to be the most cost-effective product, but the choice of vaccine should be re-evaluated as more evidence emerges on the price, incremental delivery cost, wastage, and impact associated with each of the different rotavirus vaccines.Population health, policies and services (PPS)Global Health and Tropical Medicine (GHTM)Instituto de Higiene e Medicina Tropical (IHMT)RUNLourenço Guimarães, EsperançaChissaque, AssucênioPecenka, ClintClark, AndrewVaz, BasíliaBanze, ArlindoCanana, NeideRomão, Clésiodo Rosário Oliveira Martins, Mariade Deus, NilsaDebellut, Frédéric2022-11-22T22:28:03Z2022-08-262022-08-26T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article9application/pdfhttp://hdl.handle.net/10362/145718eng0264-410XPURE: 46703091https://doi.org/10.1016/j.vaccine.2022.07.044info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:26:19Zoai:run.unl.pt:10362/145718Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:52:13.646410Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Cost-effectiveness of rotavirus vaccination in Mozambique
title Cost-effectiveness of rotavirus vaccination in Mozambique
spellingShingle Cost-effectiveness of rotavirus vaccination in Mozambique
Lourenço Guimarães, Esperança
Cost-effectiveness
Diarrhea
Modelling
Mozambique
Rotavirus
UNIVAC
Vaccination
Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases
SDG 3 - Good Health and Well-being
title_short Cost-effectiveness of rotavirus vaccination in Mozambique
title_full Cost-effectiveness of rotavirus vaccination in Mozambique
title_fullStr Cost-effectiveness of rotavirus vaccination in Mozambique
title_full_unstemmed Cost-effectiveness of rotavirus vaccination in Mozambique
title_sort Cost-effectiveness of rotavirus vaccination in Mozambique
author Lourenço Guimarães, Esperança
author_facet Lourenço Guimarães, Esperança
Chissaque, Assucênio
Pecenka, Clint
Clark, Andrew
Vaz, Basília
Banze, Arlindo
Canana, Neide
Romão, Clésio
do Rosário Oliveira Martins, Maria
de Deus, Nilsa
Debellut, Frédéric
author_role author
author2 Chissaque, Assucênio
Pecenka, Clint
Clark, Andrew
Vaz, Basília
Banze, Arlindo
Canana, Neide
Romão, Clésio
do Rosário Oliveira Martins, Maria
de Deus, Nilsa
Debellut, Frédéric
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Population health, policies and services (PPS)
Global Health and Tropical Medicine (GHTM)
Instituto de Higiene e Medicina Tropical (IHMT)
RUN
dc.contributor.author.fl_str_mv Lourenço Guimarães, Esperança
Chissaque, Assucênio
Pecenka, Clint
Clark, Andrew
Vaz, Basília
Banze, Arlindo
Canana, Neide
Romão, Clésio
do Rosário Oliveira Martins, Maria
de Deus, Nilsa
Debellut, Frédéric
dc.subject.por.fl_str_mv Cost-effectiveness
Diarrhea
Modelling
Mozambique
Rotavirus
UNIVAC
Vaccination
Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases
SDG 3 - Good Health and Well-being
topic Cost-effectiveness
Diarrhea
Modelling
Mozambique
Rotavirus
UNIVAC
Vaccination
Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases
SDG 3 - Good Health and Well-being
description Funding Information: The authors received funding from Bill and Melinda Gates Foundation (OPP1147721), through PATH subaward number: GAT.2111-01707508-SUB. Funding Information: We thank the EPI and the NITAG, from Mozambique for their support and commitment to the present analysis. We also thank PATH team for the technical support and Laura Kallen (from PATH) for linguistic revision of the manuscript. The authors received funding from Bill and Melinda Gates Foundation (OPP1147721), through PATH subaward number: GAT.2111-01707508-SUB. Publisher Copyright: © 2022 The Authors
publishDate 2022
dc.date.none.fl_str_mv 2022-11-22T22:28:03Z
2022-08-26
2022-08-26T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/145718
url http://hdl.handle.net/10362/145718
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0264-410X
PURE: 46703091
https://doi.org/10.1016/j.vaccine.2022.07.044
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138114313125888

Registros relacionados